The effects of basic fibroblast growth factor (bFGF) on the breaking strength of acute incisional wounds.
Many researchers have reported the effects of cytokines on ulcers, especially on chronic ulcers. However, the long-term influences of cytokines on acute incisional wounds with respect to breaking strength, quality of the scar etc. have not been elucidated completely. In the present study, the breaking strength of scars produced by full thickness incisional wounds of the skin created on backs of rabbits were compared when the wounds were treated by conventional suturing or with basic fibroblast growth factor (bFGF) in addition to suturing. We administered bFGF to full thickness acute incisional wounds of the skin created on backs of rabbits. The breaking strengths of wounds treated by conventional suturing and those treated with bFGF soon after the operation were compared as were the conditions of the scars after long-term follow up of up to 7 weeks. They were also examined histopathologically. Administration of bFGF at the time of wound closure, especially 1.0 microg in amount per cm, increased the breaking strength significantly compared to the control group from 5 weeks after the operation. Moreover, histopathological examination revealed that there was rich vascularization soon after the operation and an arrangement of collagen fibers which lenticulated horizontally from the 5th week and later after the operation in the bFGF treated groups in a dose dependent manner. This study demonstrates that administration of bFGF at the time of wound closure significantly increased the breaking strength compared to the control group from 5 weeks after the operation. And the administration of bFGF also improved the quality of the scar, the condition of the scar by surface condition by inspection as well as the width of scar at histological evaluations. So we think this cytokine may be highly effective clinically. This may be especially true for patients whose wound healing process tends to be delayed such as aged patients or when high breaking strength is recommended even for patients with normal wound healing potential.
Ono
Ichiro
I
Department of Dermatology, Sapporo Medical University School of Medicine, South-1 West-16 Chuo-ku, Sapporo, Japan. ichiro@sapmed.ac.jp
D000818:Animals; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D011817:Rabbits; D013537:Sutures; D013718:Tensile Strength / Q000187:drug effects*; D013997:Time Factors; D014945:Wound Healing; D014950:Wounds, Penetrating / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery
D016222:Fibroblast Growth Factor 2